Dulaglutide peptide (LY2189265)

About the Target

Dulaglutide is a GLP-1 receptor agonist approved for the management of hyper glycaemia in people with type 2 diabetes in many countries. The mapped target for this entry is Glucagon-like peptide-1 receptor (GLP1R). This target context is most often investigated as part of ligand-responsive signaling, where receptor occupancy can reshape downstream second-messenger output, trafficking, secretion, excitability, or transcriptional programs. In endocrine signaling studies, investigators commonly track ligand-responsive signaling, secretion, and endocrine feedback. For experimental design, that means the peptide is often chosen to compare acute signaling with longer adaptive responses in the same system.

Research Context

As an agonist-format peptide, it is typically used to trigger pathway activation on demand and to compare acute signaling events with longer adaptive changes such as receptor desensitization or altered transcriptional output. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses. The available sequence cue can also be useful for tracking construct identity across screening and follow-up experiments.

• pair peptide treatment with pathway-proximal signaling or trafficking readouts whenever possible
• compare responses across cell states or model systems with different receptor abundance
• distinguish primary target engagement from downstream adaptation during longer incubations

Experimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.

Format Considerations

The standard product format is most useful for reproducible baseline experiments, matched comparative studies, and workflows that need a consistent reagent across assay repeats. In comparative workflows, documenting the provided sequence cue (His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser- Tyr-Leu-Glu-Glu-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-Gly) can support traceability in comparative studies. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.